With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising effectiveness.

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can ...

The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this limitation through advanced molecular engineering techniques.

Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...

An oral drug from Pfizer causes a similar amount of weight loss as the blockbuster Ozempic injection, made by rival Novo Nordisk, according to results from a phase two clinical trial. The results were ...

For India, where long-term adherence is a major challenge, a once-monthly GLP-1 therapy could improve patient acceptance and sustained obesity management, says Dr Anoop Misra, Chairman at Fortis CDOC ...